nach oben

Erschienen in:

08.04.2023 | Original Article

Resveratrol prevents ovariectomy-induced bone quality deterioration by improving the microarchitectural and biophysicochemical properties of bone

verfasst von: Sevval Ozturk, Ibrahim Cuneyit, Fatih Altuntas, Ege Riza Karagur, Aysegul Cort Donmez, Mert Ocak, Mustafa Unal, Mehmet Sarikanat, Baris Ozgur Donmez

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Osteoporosis is a major health problem that is very common worldwide and is characterized by both low bone density and deterioration in bone quality. New treatment options without side effects have become an active area of research in recent years. This study was designed to investigate the preventive effects of resveratrol on bone quality deterioration caused by ovariectomy.

Materials and Methods

Sixty rats were randomly divided into five groups (12 animals per group): Control, Sham-operated (SHAM), ovariectomized (OVX), OVX + Resveratrol-40 mg/kg/day (OVX + Res40), OVX + Resveratrol-80 mg/kg/day (OVX + Res80). Resveratrol was administered by oral gavage (40 and 80 mg/kg/day) for ten weeks. Micro-CT measurements, biomechanical testing, Raman spectroscopy analysis, and RT-PCR analysis were performed. ALP, OCN, TAS, and TOS levels were also measured from blood serum.

Results

Bone strength, bone volume/total volume, trabecular volume, and trabecular thickness were higher in the OVX + RES-80 group than in the OVX group. Resveratrol increased osteogenic differentiation, as the expression of osteogenic markers ALP, Col1A1, Runx2, OPG, OCN increased in both OVX + RES-80 and OVX + RES-40 groups compared to the OVX group. 80 mg/kg/day resveratrol administration decreased the levels of ALP, OCN and TOS in ovariectomized rats. Raman spectroscopy findings showed a preventive effect of resveratrol administration against ovariectomy-induced deterioration in biophysiochemical properties of bone tissue.

Conclusion

This study revealed that administration of different doses of 80 mg/kg/day and 40 mg/kg/day of resveratrol had protective effects on bone quality deterioration caused by ovariectomy.

Tou JC (2015) Resveratrol supplementation affects bone acquisition and osteoporosis: Pre-clinical evidence toward translational diet therapy. Biochim Biophys Acta 1852:1186–1194. https://doi.org/10.1016/j.bbadis.2014.10.003CrossRefPubMed

Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413. https://doi.org/10.1007/pl00004148CrossRefPubMed

Zeng Q, Li N, Wang Q, Feng J, Sun D, Zhang Q, Huang J, Wen Q, Hu R, Wang L, Ma Y, Fu X, Dong S, Cheng X (2019) The prevalence of osteoporosis in china, a nationwide, multicenter DXA Survey. J Bone Miner Res 34:1789–1797. https://doi.org/10.1002/jbmr.3757CrossRefPubMed

Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475. https://doi.org/10.1359/jbmr.061113CrossRefPubMed

Holroyd C, Cooper C, Dennison E (2008) Epidemiology of osteoporosis. Best Pract Res Clin Endocrinol Metab 22:671–685. https://doi.org/10.1016/j.beem.2008.06.001CrossRefPubMed

Beral V, Reeves G, Bull D, Green J (2011) Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 103:296–305. https://doi.org/10.1093/jnci/djq527CrossRefPubMedPubMedCentral

Chlebowski RT, Anderson G, Manson JE, Pettinger M, Yasmeen S, Lane D, Langer RD, Hubbell FA, McTiernan A, Hendrix S, Schenken R, Stefanick ML (2010) Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol 28:2690–2697. https://doi.org/10.1200/JCO.2009.24.8799CrossRefPubMedPubMedCentral

Zhao M, Liu J, Zhang X, Peng L, Li C, Peng S (2009) 3D QSAR of novel estrogen-RGD peptide conjugates: getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT. Bioorg Med Chem 17:3680–3689. https://doi.org/10.1016/j.bmc.2009.03.057CrossRefPubMed

Smoliga JM, Baur JA, Hausenblas HA (2011) Resveratrol and health–a comprehensive review of human clinical trials. Mol Nutr Food Res 55:1129–1141. https://doi.org/10.1002/mnfr.201100143CrossRefPubMed

10.

Novelle MG, Wahl D, Dieguez C, Bernier M, de Cabo R (2015) Resveratrol supplementation: Where are we now and where should we go? Ageing Res Rev 21:1–15. https://doi.org/10.1016/j.arr.2015.01.002CrossRefPubMedPubMedCentral

11.

Feng J, Liu S, Ma S, Zhao J, Zhang W, Qi W, Cao P, Wang Z, Lei W (2014) Protective effects of resveratrol on postmenopausal osteoporosis: regulation of SIRT1-NF-kappaB signaling pathway. Acta Biochim Biophys Sin (Shanghai) 46:1024–1033. https://doi.org/10.1093/abbs/gmu103CrossRefPubMed

12.

Zhao M, Ko SY, Garrett IR, Mundy GR, Gutierrez GE, Edwards JR (2018) The polyphenol resveratrol promotes skeletal growth in mice through a sirtuin 1-bone morphogenic protein 2 longevity axis. Br J Pharmacol 175:4183–4192. https://doi.org/10.1111/bph.14477CrossRefPubMedPubMedCentral

13.

Yu T, Wang Z, You X, Zhou H, He W, Li B, Xia J, Zhu H, Zhao Y, Yu G, Xiong Y, Yang Y (2020) Resveratrol promotes osteogenesis and alleviates osteoporosis by inhibiting p53. Aging (Albany NY) 12:10359–10369. https://doi.org/10.18632/aging.103262CrossRefPubMed

14.

Shakibaei M, Buhrmann C, Mobasheri A (2011) Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells. J Biol Chem 286:11492–11505. https://doi.org/10.1074/jbc.M110.198713CrossRefPubMedPubMedCentral

15.

Feng YL, Jiang XT, Ma FF, Han J, Tang XL (2018) Resveratrol prevents osteoporosis by upregulating FoxO1 transcriptional activity. Int J Mol Med 41:202–212. https://doi.org/10.3892/ijmm.2017.3208CrossRefPubMed

16.

Bhattarai G, Poudel SB, Kook SH, Lee JC (2016) Resveratrol prevents alveolar bone loss in an experimental rat model of periodontitis. Acta Biomater 29:398–408. https://doi.org/10.1016/j.actbio.2015.10.031CrossRefPubMed

17.

Omnia Ameen RIYaYMN (2020) Activation of FoxO1/SIRT1/RANKL/OPG pathway may underlie the therapeutic effects of resveratrol on aging-dependent male osteoporosis. BMC musculoskel disord. 21:389

18.

Lin Q, Huang YM, Xiao BX, Ren GF (2005) Effects of resveratrol on bone mineral density in ovarectomized rats. Int J Biomed Sci 1:76–81PubMedPubMedCentral

19.

Wang X, Chen L, Peng W (2017) Protective effects of resveratrol on osteoporosis via activation of the SIRT1-NF-kappaB signaling pathway in rats. Exp Ther Med 14:5032–5038. https://doi.org/10.3892/etm.2017.5147CrossRefPubMedPubMedCentral

20.

Wang W, Zhang LM, Guo C, Han JF (2020) Resveratrol promotes osteoblastic differentiation in a rat model of postmenopausal osteoporosis by regulating autophagy. Nutr Metab (Lond) 17:29. https://doi.org/10.1186/s12986-020-00449-9CrossRefPubMed

21.

Zhao H, Li X, Li N, Liu T, Liu J, Li Z, Xiao H, Li J (2014) Long-term resveratrol treatment prevents ovariectomy-induced osteopenia in rats without hyperplastic effects on the uterus. Br J Nutr 111:836–846. https://doi.org/10.1017/S0007114513003115CrossRefPubMed

22.

Jiang Y, Luo W, Wang B, Wang X, Gong P, Xiong Y (2020) Resveratrol promotes osteogenesis via activating SIRT1/FoxO1 pathway in osteoporosis mice. Life Sci 246:117422. https://doi.org/10.1016/j.lfs.2020.117422CrossRefPubMed

23.

Khera A, Kanta P, Kalra J, Dumir D (2019) Resveratrol restores the level of key inflammatory cytokines and RANKL/OPG ratio in the femur of rat osteoporosis model. J Women Aging 31:540–552. https://doi.org/10.1080/08952841.2018.1522126CrossRefPubMed

24.

Zhao L, Wang Y, Wang Z, Xu Z, Zhang Q, Yin M (2015) Effects of dietary resveratrol on excess-iron-induced bone loss via antioxidative character. J Nutr Biochem 26:1174–1182. https://doi.org/10.1016/j.jnutbio.2015.05.009CrossRefPubMed

25.

Durbin SM, Jackson JR, Ryan MJ, Gigliotti JC, Alway SE, Tou JC (2014) Resveratrol supplementation preserves long bone mass, microstructure, and strength in hindlimb-suspended old male rats. J Bone Miner Metab 32:38–47. https://doi.org/10.1007/s00774-013-0469-2CrossRefPubMed

26.

Karimian E, Tamm C, Chagin AS, Samuelsson K, Kjartansdottir KR, Ohlsson C, Savendahl L (2013) Resveratrol treatment delays growth plate fusion and improves bone growth in female rabbits. PLoS ONE 8:e67859. https://doi.org/10.1371/journal.pone.0067859CrossRefPubMedPubMedCentral

27.

Nair AB, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7:27–31. https://doi.org/10.4103/0976-0105.177703CrossRefPubMedPubMedCentral

28.

Erel O (2005) A new automated colorimetric method for measuring total oxidant status. Clin Biochem 38:1103–1111. https://doi.org/10.1016/j.clinbiochem.2005.08.008CrossRefPubMed

29.

Unal M, Ahmed R, Mahadevan-Jansen A, Nyman JS (2021) Compositional assessment of bone by Raman spectroscopy. Analyst 146:7464–7490. https://doi.org/10.1039/d1an01560eCrossRefPubMedPubMedCentral

30.

Unal M, Uppuganti S, Timur S, Mahadevan-Jansen A, Akkus O, Nyman JS (2019) Assessing matrix quality by Raman spectroscopy helps predict fracture toughness of human cortical bone. Sci Rep 9:7195. https://doi.org/10.1038/s41598-019-43542-7CrossRefPubMedPubMedCentral

31.

Donmez BO, Ozdemir S, Sarikanat M, Yaras N, Koc P, Demir N, Karayalcin B, Oguz N (2012) Effect of angiotensin II type 1 receptor blocker on osteoporotic rat femurs. Pharmacol Rep 64:878–888. https://doi.org/10.1016/s1734-1140(12)70882-4CrossRefPubMed

32.

Turner CH (2002) Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 13:97–104. https://doi.org/10.1007/s001980200000CrossRefPubMed

33.

Donmez BO, Ozturk N, Sarikanat M, Oguz N, Sari R, Ozdemir S (2014) Sodium tungstate alleviates biomechanical properties of diabetic rat femur via modulation of oxidative stress. Gen Physiol Biophys 33:443–452. https://doi.org/10.4149/gpb_2014020CrossRefPubMed

34.

Lee AM, Shandala T, Nguyen L, Muhlhausler BS, Chen KM, Howe PR, Xian CJ (2014) Effects of resveratrol supplementation on bone growth in young rats and microarchitecture and remodeling in ageing rats. Nutrients 6:5871–5887. https://doi.org/10.3390/nu6125871CrossRefPubMedPubMedCentral

35.

Li Y, Tseng WJ, de Bakker CMJ, Zhao H, Chung R, Liu XS (2021) Peak trabecular bone microstructure predicts rate of estrogen-deficiency-induced bone loss in rats. Bone 145:115862. https://doi.org/10.1016/j.bone.2021.115862CrossRefPubMedPubMedCentral

36.

Mandair GS, Morris MD (2015) Contributions of Raman spectroscopy to the understanding of bone strength. Bonekey Rep 4:620. https://doi.org/10.1038/bonekey.2014.115CrossRefPubMedPubMedCentral

37.

Paschalis EP, Gamsjaeger S, Klaushofer K (2017) Vibrational spectroscopic techniques to assess bone quality. Osteoporos Int 28:2275–2291. https://doi.org/10.1007/s00198-017-4019-yCrossRefPubMed

38.

Unal M (2020) Letter to the Editor. Connect Tissue Res 61:420–422. https://doi.org/10.1080/03008207.2019.1666113CrossRefPubMed

39.

Unal M, Uppuganti S, Leverant CJ, Creecy A, Granke M, Voziyan P, Nyman JS (2018) Assessing glycation-mediated changes in human cortical bone with Raman spectroscopy. J Biophotonics. 11:201700352. https://doi.org/10.1002/jbio.201700352CrossRef

40.

Unal M, Jung H, Akkus O (2016) Novel Raman Spectroscopic Biomarkers Indicate That Postyield Damage Denatures Bone’s Collagen. J Bone Miner Res 31:1015–1025. https://doi.org/10.1002/jbmr.2768CrossRefPubMed

41.

Paschalis EP, Shane E, Lyritis G, Skarantavos G, Mendelsohn R, Boskey AL (2004) Bone fragility and collagen cross-links. J Bone Miner Res 19:2000–2004. https://doi.org/10.1359/JBMR.040820CrossRefPubMed

42.

Wang X, Xu H, Huang Y, Gu S, Jiang JX (2016) Coupling Effect of Water and Proteoglycans on the In Situ Toughness of Bone. J Bone Miner Res 31:1026–1029. https://doi.org/10.1002/jbmr.2774CrossRefPubMed

43.

Unal M, Akkus O (2015) Raman spectral classification of mineral- and collagen-bound water’s associations to elastic and post-yield mechanical properties of cortical bone. Bone 81:315–326. https://doi.org/10.1016/j.bone.2015.07.024CrossRefPubMedPubMedCentral

44.

Kawane T, Komori H, Liu W, Moriishi T, Miyazaki T, Mori M, Matsuo Y, Takada Y, Izumi S, Jiang Q, Nishimura R, Kawai Y, Komori T (2014) Dlx5 and mef2 regulate a novel runx2 enhancer for osteoblast-specific expression. J Bone Miner Res 29:1960–1969. https://doi.org/10.1002/jbmr.2240CrossRefPubMed

45.

Lin GL, Hankenson KD (2011) Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation. J Cell Biochem 112:3491–3501. https://doi.org/10.1002/jcb.23287CrossRefPubMedPubMedCentral

46.

Liu Q, Zhang X, Jiao Y, Liu X, Wang Y, Li SL, Zhang W, Chen FM, Ding Y, Jiang C, Jin Z (2018) In vitro cell behaviors of bone mesenchymal stem cells derived from normal and postmenopausal osteoporotic rats. Int J Mol Med 41:669–678. https://doi.org/10.3892/ijmm.2017.3280CrossRefPubMed

47.

Gao Y, Patil S, Jia J (2021) The development of molecular biology of osteoporosis. Int J Mol Sci. https://doi.org/10.3390/ijms22158182CrossRefPubMedPubMedCentral

48.

Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342. https://doi.org/10.1038/nature01658CrossRefPubMed

49.

Walsh MC, Choi Y (2014) Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol 5:511. https://doi.org/10.3389/fimmu.2014.00511CrossRefPubMedPubMedCentral

50.

Minamizaki T, Sakurai K, Hayashi I, Toshishige M, Yoshioka H, Kozai K, Yoshiko Y (2020) Active sites of human MEPE-ASARM regulating bone matrix mineralization. Mol Cell Endocrinol. 517:110931. https://doi.org/10.1016/j.mce.2020.110931CrossRefPubMed

51.

Minamizaki T, Yoshiko Y (2015) The bioactive acidic serine- and aspartate-rich motif peptide. Curr Protein Pept Sci 16:196–202. https://doi.org/10.2174/1389203716666150206122839CrossRefPubMed

52.

Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA (2003) Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 278:1998–2007. https://doi.org/10.1074/jbc.M203250200CrossRefPubMed

53.

David V, Martin A, Hedge AM, Rowe PS (2009) Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology 150:4012–4023. https://doi.org/10.1210/en.2009-0216CrossRefPubMedPubMedCentral

54.

Guo D, Keightley A, Guthrie J, Veno PA, Harris SE, Bonewald LF (2010) Identification of osteocyte-selective proteins. Proteomics 10:3688–3698. https://doi.org/10.1002/pmic.201000306CrossRefPubMedPubMedCentral

Titel: Resveratrol prevents ovariectomy-induced bone quality deterioration by improving the microarchitectural and biophysicochemical properties of bone
verfasst von: Sevval Ozturk
Ibrahim Cuneyit
Fatih Altuntas
Ege Riza Karagur
Aysegul Cort Donmez
Mert Ocak
Mustafa Unal
Mehmet Sarikanat
Baris Ozgur Donmez
Publikationsdatum: 08.04.2023
Verlag: Springer Nature Singapore
Erschienen in: Journal of Bone and Mineral Metabolism / Ausgabe 4/2023
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-023-01416-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Resveratrol prevents ovariectomy-induced bone quality deterioration by improving the microarchitectural and biophysicochemical properties of bone